Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push VA hits pause on future rollouts of EHR until 2023 while lawmakers raise fresh concerns about patient safety risks Should Merck buy Seagen—and at what price? Analysts and investors weigh in Medtronic reinforces spine surgery portfolio with FDA nod for ligament-augmenting implant Optum launches new solution aimed at driving down unnecessary testing Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact As biosimilars gain steam, Amgen exec lays out its Humira copycat plans FDA adds Class I tag to Dräger’s recall of 36K ventilator filters Pfizer's Russian profit pledge bears fruit with $5M initial gift, CEO says CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer GE Healthcare debuts wireless, wearable hospital patient monitor Eli Lilly finds stigma is one of the worst parts of migraine as it aims to help break the taboo CMS mulls $810M cut to home health Medicare payments ViiV, Gilead and Janssen notch top scores with HIV/AIDS patient groups; pricing, access still pain points Featured Story | By Annalee Armstrong,James Waldron Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million). read more |
| |
|---|
|
| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
Top Stories By Heather Landi The Department of Veterans Affairs will push off deployment of a new electronic medical records system to additional medical facilities until 2023 to address outages that have plagued the software at current sites. read more By Angus Liu After a report of a potential Seagen acquisition by Merck emerged, industry watchers have been busy assessing whether a deal would indeed help Merck reduce its dependence on Keytruda and boost return for investors. While Seagen investors liked a $215-per-share price assumed by SVB Securities, Merck shareholders have some doubts. read more By Andrea Park Medtronic’s line of devices to strengthen the spine just got a bit stronger itself. read more By Paige Minemyer Optum is launching a new health plan solution that aims to reduce unnecessary testing and ensure that patients are receiving the screenings that are best for them. read more By Nick Paul Taylor One year after Intellia’s landmark data, Novartis is making a play for the in vivo gene editing market. The move sees the Swiss pharma pay Precision BioSciences $75 million upfront, with up to $1.4 billion in milestones, to secure rights to a potential treatment for sickle cell disease and beta thalassemia. read more By Zoey Becker As the industry sees more biosimilar uptake, Amgen says it's well prepared. Last week, the company presented a preview of its annual trends in biosimilars report at the BIO 2022 convention in San Diego. Next year, Amgen is planning to really make its mark with the industry's first US biosimilar of AbbVie's Humira. read more By Andrea Park As ventilators and other respiratory devices became more crucial than ever throughout the COVID-19 pandemic, so too did any safety issues embedded in the machines become more apparent. read more By Fraiser Kansteiner After Russia’s war in Ukraine escalated sharply in February, Pfizer swiftly pledged to donate the sum of its Russian profits, declaring the cash would help causes that provide direct support to the people of Ukraine. Three months later, the company says it’s making good on that promise. read more By Gabrielle Masson Gene editing giant CRISPR Therapeutics is moving away from multiple myeloma candidate CTX120, while a small, separate dataset released yesterday sent the company’s stock plummeting. read more By Conor Hale Cleared for use in Europe, GE Healthcare aims to make it easier for clinicians to keep track of patients vital signs without performing routine check-ins. read more By Sharon Klahr Coey It turns out that even more than the blinding pain, the nausea, the photosensitivity or crushing fatigue, the worst part of migraine is often the stigma attached to it. Those results are part of Eli Lilly’s fourth OVERCOME migraine data study. read more By Robert King CMS is proposing an $810 million cut to Medicare payments to home health agencies in 2023 due in part to a change to how the agency calculates payments. read more By Natalie Missakian Patient groups may view pharma more favorably thanks to its work during the pandemic, but HIV and AIDS patients groups are a tougher sell, according to a new survey. read more |
